GlaxoSmithKline plc Is Still A Better Pick Than AstraZeneca plc

GlaxoSmithKline plc (LON: GSK) has made mistakes but the company is still a better bet than AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaIt has been a terrible year for GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and more bad news could be around the corner. Indeed, even after being found guilty of bribing medical officials within China and being fined £300m, the company is still facing an investigation by British and American authorities.

Still, the conclusion of the Chinese bribery case and subsequent fine has removed much speculation and uncertainty about the company’s future. Some analysts had been worried that China would slap a huge fine on Glaxo, one so large that the company’s dividend payout would come under pressure. However, a £300m fine is manageable for Glaxo, which reported pre-tax profits of £6.6bn last year.

The best pick

With uncertainty removed, Glaxo has become a better pick than AstraZeneca (LSE: AZN) (NYSE: AZN.US) as the company looks attractive on several key valuation metrics, as well as fundamental factors.

In particular, at present levels Astra trades at a forward P/E of 16.5 as the company’s earnings per share are expected to fall by 14% this year. In addition, earnings are expected to fall a further 7% during 2015. Nevertheless, the market continues to speculate that US pharmaceutical giant Pfizer will make another attempt to acquire Astra, which explains Astra’s high valuation. 

On the other hand, Glaxo trades at a forward P/E of 15, with earnings growth of 5% pencilled in for 2015. This puts the company on a 2015 P/E of 14.4. So, Glaxo is cheaper than its smaller peer, while Glaxo’s earnings are expected to grow faster over the next two years.

Then there’s Glaxo’s dividend yield, which is currently 5.4%, compared to Astra’s lowly 3.9%. 

Bright future 

Glaxo easily trumps Astra on valuation grounds but what about the company’s prospects? Well, analysts have consistently praised the strength of Glaxo’s treatment pipeline over the past 12 months, ranking it the best in the industry. The company has 40 new treatments under development in total. Then there’s the company’s joint venture with Swiss pharmaceutical giant Novartis, which will see the two groups create a world-leading consumer healthcare company.

Compared to Glaxo, Astra’s treatment pipeline is more specialist. However, the company’s management believes that the group has “one of the most exciting pipelines in the industry,” although Astra’s fast-evolving pipeline is focused on a new area of cancer research known as immuno-oncology. Only time will tell if Astra’s focus on these new treatments will pay off.

The bottom line

All in all, it has been a tough year for Glaxo but now the company has settled with Chinese authorities, things are looking up. With uncertainty removed Glaxo’s low valuation makes it a better pick than Astra, which looks expensive based on the company’s falling income. Moreover, analysts believe that Glaxo’s pipeline of treatments under development has plenty of potential.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »